Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update
forward-looking statements.
About Daiichi Sankyo Company, Limited
A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in
2005 through the merger of two leading Japanese pharmaceutical companies.
This integration created a more robust organization that allows for
continuous development of novel drugs that enrich the quality of life for
patients around the world. Areas of primary focus for Daiichi Sankyo research
and development are thrombotic disorders, malignant neoplasm, diabetes
mellitus, and autoimmune disorders. Equally important to the company are
hypertension, hyperlipidemia or atherosclerosis, and bacterial infections.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, IN, Lilly provides answers -
through medicines and information - for some of the world's most urgent
medical needs.
P-LLY
(i) American Heart Association. Heart Disease and Stroke Statistics -
2008 Update.
final.pdf. Accessed December 9, 2008.
(ii) British Heart Foundation Health Promotion Research Group. European
Cardiovascular Disease Statistics 2008,
December 9, 2008.
(iii) WebMD Medical Reference in Collaboration with the Cleveland Clinic.
Heart Disease: Coronary Artery Disease.
2008.
SOURCE: Eli Lilly and Company
CONTACT: Tammy Hull of Eli Lilly and Company,
+1-317-651-9116 (office),
+1-317-614-5132 (cell); or
Kim Wix of Daiichi Sankyo (U.S.A.),
+1-973-944-2338 (office),
+1-908-656-5447 (cell), or
Shigemichi Kondo of Daiichi Sankyo (Tokyo),
81-3-6225-1126 (office)
NEWS 
